News articles about Endo International plc – (NASDAQ:ENDP) have been trending somewhat positive recently, according to AlphaOne. The research firm, a division of Accern, identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real time. AlphaOne ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Endo International plc – earned a media sentiment score of 0.08 on AlphaOne’s scale. AlphaOne also assigned media headlines about the company an impact score of 64 out of 100, meaning that recent press coverage is somewhat likely to have an effect on the company’s share price in the near term.
Here are some of the news stories that may have impacted Alpha One’s rankings:
- Equities Analysts Offer Predictions for Endo International plc -‘s Q1 2017 Earnings (ENDP) (americanbankingnews.com)
- Stocks in Focus: ING Groep NV (ADR) (NYSE:ING), Endo International plc – Ordinary Shares (NASDAQ:ENDP), New … – Wall Street Times (press release) (wallstreetnews24.com)
- Biotech Movers: Organovo, Endo, Omeros (finance.yahoo.com)
- Endo International plc – (ENDP) Stock Rating Reaffirmed by Canaccord Genuity (americanbankingnews.com)
- Endo International plc – (ENDP) Given “Hold” Rating at Canaccord Genuity (semiconductors.einnews.com)
ENDP has been the topic of several analyst reports. Susquehanna Bancshares Inc upgraded Endo International plc – from a “neutral” rating to a “positive” rating in a report on Tuesday, January 31st. JPMorgan Chase & Co. cut Endo International plc – from an “overweight” rating to a “neutral” rating and set a $20.00 price objective for the company. in a research report on Friday, January 20th. Zacks Investment Research raised Endo International plc – from a “sell” rating to a “hold” rating in a research report on Tuesday, January 10th. Guggenheim reissued a “buy” rating and issued a $35.00 price objective on shares of Endo International plc – in a research report on Tuesday, February 28th. Finally, Piper Jaffray Companies set a $12.00 price objective on Endo International plc – and gave the company a “hold” rating in a research report on Friday, January 27th. Thirteen analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $20.72.
Shares of Endo International plc – (NASDAQ:ENDP) traded down 1.81% on Friday, reaching $10.29. The company had a trading volume of 5,835,433 shares. The company’s 50-day moving average price is $10.84 and its 200-day moving average price is $14.65. The firm’s market capitalization is $2.29 billion. Endo International plc – has a 52-week low of $9.70 and a 52-week high of $35.34.
Endo International plc – (NASDAQ:ENDP) last announced its quarterly earnings data on Tuesday, February 28th. The company reported $1.77 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.14. Endo International plc – had a positive return on equity of 15.95% and a negative net margin of 3.32%. The business earned $1.24 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same period in the prior year, the company earned $1.36 EPS. Endo International plc -‘s revenue for the quarter was up 15.6% on a year-over-year basis. On average, analysts predict that Endo International plc – will post $3.60 earnings per share for the current year.
In related news, Director Nancy J. Hutson sold 5,325 shares of the company’s stock in a transaction on Thursday, March 9th. The stock was sold at an average price of $10.82, for a total transaction of $57,616.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.70% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/2486020/somewhat-favorable-media-coverage-somewhat-likely-to-impact-endo-international-plc-endp-stock-price.html.
About Endo International plc –
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International plc - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International plc - and related companies with MarketBeat.com's FREE daily email newsletter.